CLL

December 4th 2023

Results from a four-year follow-up of a phase 3 trial determined that the combination of Imbruvica and Venclexta provided benefits for untreated patients with CLL.

December 2nd 2023

The Food and Drug Administration approved Jaypirca for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received two or more lines of therapy.

November 17th 2023

The Food and Drug Administration accepted a Priority Review for Breyanzi for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

November 8th 2023

Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated Patient® CLL Summit.